An International Publisher for Academic and Scientific Journals
Author Login
Scholars Journal of Medical Case Reports | Volume-14 | Issue-11
Small Cell Lung Cancer: Experience from the Oncology-Radiotherapy Department of Mohammed VI University Hospital Marrakech, Morocco
Achraf Zaridi *, H. El Ghozail, S. Laatitioui, R. Ousalm, T. Igarramen, M. Saadoune, N. Oumghar, S. Barkiche, M. Darfaoui, A. El Omrani, M. Khouchani
Published: Nov. 21, 2026 |
14
11
Pages: 2801-2806
Downloads
Abstract
Small cell lung cancer (SCLC) accounts for 10–15% of lung cancers and is the most aggressive histological subtype, most patients presenting with disseminated disease. Local data on its presentation and management are scarce. This study aimed to describe the epidemiological, clinical, paraclinical, therapeutic and prognostic profile of SCLC in the Oncology-Radiotherapy Department of Mohammed VI University Hospital Marrakech, Morocco. We conducted a retrospective, descriptive observational study of 28 histologically confirmed SCLC cases managed between December 2022 and December 2025. Data were extracted from the department’s register and medical records. SCLC represented 5% of all lung cancers diagnosed during the period, with a decreasing trend over the years. Median age was 61 years (range 43–70) and 93% of patients were men. Chronic smoking was found in 93% of cases (71% with more than 20 pack-years). The most frequent presenting symptoms were dyspnea (93%), chest pain (50%), and hemoptysis (14%). Extensive-stage disease was present in 26 patients (93%); metastases involved the bone (57%), lung (28%), adrenal glands (28%), brain (28%) and liver (21%). 57% of patients had two or more metastatic sites. First-line platinum–etoposide chemotherapy was delivered to 22 patients (79%), whereas 6 (21%) received supportive care only because of poor performance status or contraindications. Complete response was achieved in 14% of the 14 evaluable patients. Hematological toxicity was the most frequent (anemia 64%, neutropenia 43%). Median overall survival was 7.6 months, with a 1-year survival of 11%. SCLC in this Moroccan hospital series is characterized by late diagnosis, heavy tobacco exposure and poor survival. These findings underscore the need for tobacco control, early diagnosis, multidisciplinary decision-making and improved access to anticancer drugs.


